Jaguar Health, Inc. earnings per share and revenue
On Nov 18, 2025, JAGX reported earnings of -6.28 USD per share (EPS) for Q3 25, missing the estimate of -5.18 USD, resulting in a -21.20% surprise. Revenue reached 3.08 million, compared to an expected 3.80 million, with a -18.97% difference. The market reacted with a -8.03% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -4.34 USD, with revenue projected to reach 4.30 million USD, implying an decrease of -30.89% EPS, and increase of 39.32% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were Jaguar Health, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Jaguar Health, Inc. reported EPS of -$6.28, missing estimates by -21.2%, and revenue of $3.08M, -18.97% below expectations.
How did the market react to Jaguar Health, Inc.'s Q3 2025 earnings?
The stock price moved down -8.03%, changed from $1.80 before the earnings release to $1.66 the day after.
When is Jaguar Health, Inc. expected to report next?
The next earning report is scheduled for Mar 30, 2026.
What are the forecasts for Jaguar Health, Inc.'s next earnings report?
Based on 3
analysts, Jaguar Health, Inc. is expected to report EPS of -$4.34 and revenue of $4.30M for Q4 2025.